SynAct Pharma AB (STO: SYNACT)

Market Cap	364.65M
Revenue (ttm)	n/a
Net Income (ttm)	-165.96M
Shares Out	41.30M
EPS (ttm)	-4.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	326,706
Open	7.80
Previous Close	7.73
Day's Range	7.56 - 10.67
52-Week Range	4.98 - 32.00
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2024

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SYNACT

Financial Performance

In 2023, Alzinova AB's revenue was 19.87 million, an increase of 19.49% compared to the previous year's 16.63 million. Losses were -16.48 million, 25.9% more than in 2022.